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Screening for prostate 
cancer: Controversy? 
What controversy?
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for the absence of a reduction in mortality in the p l c o  
trial and in comparison with the difference seen in 
the e r s p c trial. The truth of the matter is the p s a test 
should not be used at all in screening for prostate 
cancer in the manner it has heretofore been used. 
Prostate-specific antigen, discovered in 1970 5,6, is a 
normal component of the prostate. It is not cancer-
specific. Rather, it is present in the normal, benign, 
and malignant prostate 7. When the U.S. Food and 
Drug Administration (f d a ) approved the p s a test in 
1994 for screening, the approval was not based on rig-
orous study of the specificity or sensitivity of the test. 
The f d a  never looked at the benefits and risks beyond 
a 3.8% detection rate compared with a 0.8%–1.4% 
detection rate for d r e .
The ability of the p s a test to identify men with 
prostate cancer is slightly better than that of flipping 
a coin. Further, prostate cancer is an age-related dis-
ease, and the p s a test may merely precipitate a biopsy, 
wherein, related to age, the biopsied individual may 
or may not have cancer—a finding that, according 
to some, may be related to “how hard it (i.e., cancer) 
is looked for” 8. With approximately 45%–80% of 
men between the ages of 50 and 75 years of age (the 
age-range of the men in the p l c o  and e r s p c trials) pos-
sessing indolent or clinically insignificant cancers 9, 
the detection of prostate cancer by p s a test, given its 
absence of cancer specificity, has more than likely 
been a serendipitous observation. Therefore, based 
on the initial studies of p s a  5–7 and the subsequent 
observations of one of us (RJA), the interim results 
from the p l c o  and e r s p c trials showed exactly what 
we would have expected.
Although the e r s p c study was “designed to show 
a 25% statistically significant reduction in possible 
prostate cancer mortality after screening” 10, it found 
only a 20% reduction in mortality. In addition, if the 
inconsistencies between e r s p c study sites—method-
ology, frequency of screening, and p s a cutoff points 
(that is, 3.0 vs. 4.0) as an indication for biopsy—are 
looked at, the data may reasonably be questioned. 
With further reference to the 20% reduction in pros-
tate cancer mortality between the screened and the 
unscreened groups, the assumption is made that, even 
The purpose of screening is to identify preclinical 
and asymptomatic cases of a disease in a population 
at risk—as opposed to making a diagnosis based on a 
patient’s presentation with symptoms and disease.
The use of the prostate-specific antigen (p s a) test 
and a digital rectal examination (d r e) to screen for 
prostate cancer—and whether such use can reduce 
prostate cancer–specific mortality—has universally 
been regarded as controversial despite the publication 
of more than 1000 articles in the medical and scien-
tific literature. In fact, in spite of national guidelines 
by the Canadian Task Force on Preventive Health 
Care, which do not recommend p s a screening for 
prostate cancer in asymptomatic men 1, 72% of Ca-
nadian men in a national survey reported receiving 
p s a screening 2. And, quoting from a publication by 
investigators from the Centre for Chronic Disease 
Prevention and Control, Public Health Agency of 
Canada, “we wait for randomized controlled trial 
evidence of the effectiveness of p s a screening in 
reducing mortality due to prostate cancer” 2.
The long anticipated wait for Canadians and others 
ended, in part, in March of this year with the publica-
tion of interim data from 7–10 years of follow-up in 
two large ongoing randomized screening trials 3,4. The 
trials were thought to be decisively designed to resolve 
the controversy over whether screening for prostate 
cancer reduces mortality. The Prostate, Lung, Col-
orectal and Ovarian (p l c o ) trial, started in 1993 in the 
United States, and the European Randomized Study of 
Screening for Prostate Cancer (e r s p c), started in 1994, 
respectively enrolled nearly 77,000 and 182,000 men 
randomly assigned to receive screening or not.
The p l c o  trial 3 found no difference in mortality 
from combined screening with the p s a test and d r e  
through 10 years; the e r s p c trial 4 reported that p s a 
screening without d r e  was associated through 9 years 
with a 20% reduction in mortality from prostate can-
cer. With due consideration to the stated 20% reduc-
tion in mortality, it is noted that 1410 men needed to 
be screened and 48 men treated to prevent 1 cancer 
death, thus overtreating 47 men.
In the interim since the publication of the two tri-
als, several possible explanations have been offered ABLIN and HAYTHORN
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with strict adherence to the criteria for the determi-
nation of cause of death in randomized screening 
trials for prostate cancer 10, given the small number 
of deaths in the screened (n = 261) and unscreened 
(n = 363) groups, with 20% being a relatively very 
small number, the determination could have included 
those very few cases in which the reviewers—that is, 
the cause-of-death committee—came to a different 
decision on cause of death.
Parenthetically, it is of interest to note that, in 
the absence of the inclusion of a d r e  as part of their 
screening protocol, the e r s p c trial did not follow the 
f d a -approval guidelines, which state that the p s a test 
“was approved for use in conjunction with a digital 
rectal exam” 11.
In the face of the facts and the interim results of 
the p l c o  and e r s p c trials, organizations that remain 
in support of screening for prostate cancer, particu-
larly the American Urological Association, whose 
president, John Barry, has stated that “p s a testing for 
prostate cancer remains a valuable screening tool and 
should be appropriately offered to men” 12, need to 
re-examine the dictum Primum non nocere: “First do 
no harm.”
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